Skip to Navigation
R&D JW, leading global drug development

Research pipeline

  • Discovery
  • Lead optimization
  • Pre-clinical
  • Phase Ⅰ
  • Phase II
  • Phase III
  • Registration
Category Code name Development phase Being in adjustment
NCE URC-102
 
 
 
 
 
Gouty(Jointly developed with Japan's Chugai Company)
CWP291
 
 
 
 
Acute myelogenous leukemia(Polygenetic clinics)
CWP291
 
 
 
 
Multiple myeloma(Polygenetic clinics)
CWP291
 
 
 
 
cancer of the stomach
CWP291 Oral compound
 
 
Solid cancer
WNT activators
 
 
 
Histography
WNT inhibitors
 
 
Solid cancer, fibrosis
JWP1601
 
 
 
 
Atopy, Anti-inflammatory disease
NCE
 
 
 
Solid cancer
NBE CreaVax-HCC
 
 
 
 
 
 
Liver cancer (Target operating patients)
CreaVax-HCC
 
 
 
 
 
Liver cancer (Cases of carotid chemotropics)
CreaVax-BC
 
 
 
 
 
Chorioblastoma